Compare Progressive Corp (PGR) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Progressive Corp vs Smith & Nephew plc — how do they compare? Progressive Corp trades at $219.2 (market cap $126.95B), while Smith & Nephew plc trades at $27.28 (market cap $11.10B). The key difference: Progressive Corp is far larger — about 11.4× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Progressive Corp for 81 Days and Smith & Nephew plc for 120 Days on average.
| PGR | SNN | |
|---|---|---|
Market Cap | $126.95B | $11.10B |
Volume | 2,749,438 | 1,051,703 |
Sector | Financials | Health |
52-Week High | $242.16 | $37.17 |
52-Week Low | $190.40 | $26.42 |
Typical Hold Time | 81 Days | 120 Days |
Enterprise Value | $135.16B | $14.13B |
Dividend Yield | 0.18% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Progressive Corporation (PGR) trades at $214.12, up 0.98% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with revenue growth from $49.6B in 2022 to $87.6B in 2025 and robust profitability metrics including 34.94% ROE. Recent earnings show mixed results with Q2 2026 beating expectations while Q1 2026 missed. Analyst consensus leans neutral with 52.38% hold ratings but a $222.23 price target suggests modest upside potential from current levels.
PGR presents a balanced investment case with solid fundamentals and reasonable valuation (P/E 10.97) offset by competitive pressures in personal auto insurance. The stock's technical strength and consistent revenue growth support potential upside, though investors should monitor underwriting discipline amid intensifying market competition. Key risks include execution challenges and macroeconomic sensitivity affecting insurance demand.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
